Compares two metformin doses in young people with type 2 diabetes
Compares a usual metformin dose with a higher dose in youth with type 2 diabetes.
Key facts
- Who runs it
- University of California, San Francisco
- Where
- Oakland and San Francisco, United StatesSee the 2 sites
- Trial code
- Registry title
- Precision Dosing of Metformin in Youth With T2D
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 20 people, planned
- Started
- 25 Apr 2024
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Metformin
- Record updated
- 23 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for young people aged 10-21 years with type 2 diabetes who already take regular metformin. It compares the usual metformin dose with a higher dose.
- Age
- 10-21 years
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes diagnosed by a provider at least 1 month ago.
- Earlier treatment
- Taking regular metformin (not extended-release) and a stable medication regimen for 2 weeks before screening, with no more than 20% change in insulin dose.
- Biomarker or test result
- No pancreatic autoantibodies (GAD-65, insulin, IA-2, ICA 512, Zn-T8).
Main reasons for not taking part
- Positive pancreatic autoantibodies (GAD-65, insulin, IA-2, ICA 512, Zn-T8)
- Known ongoing kidney or liver disease
- Significant mental illness or developmental delay that stops you doing study activities on your own
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Age 10-21 years
- Provider diagnosis of T2D
- Stable medication regimen for 2 weeks before screening visit (No addition or removal of medications and no more than 20% change in insulin dose)
- ≥ 1 month from T2D diagnosis
- Taking regular metformin (not extended-release formula)
- Ability to wear CGM for a total of 6 weeks while in the study
- English or Spanish speakers
- Willing to abide by recommendations and study procedures
- Willing and able to sign the Informed Consent Form (ICF) and/or has a parent or guardian willing and able to sign the ICF
- Participant and parent(s)/guardian(s) willingness to participate in all training sessions as directed by study staff. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study
Who cannot take part
- Known history of ongoing renal or hepatic disease
- Known history of significant mental illness or developmental delay impacting the ability to complete study activities independently
- Pancreatic autoantibody positivity (GAD-65, insulin, IA-2, ICA 512, Zn-T8)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 10 and 21 years old?
Where in United States
- UCSF Benioff Children's Hospital Oakland, Pediatric Diabetes ClinicOakland, United StatesContact: Shylaja Srinivasan, MDTaking people
- UCSF Benioff Children's Hospital San Francisco, Madison Clinic for Pediatric DiabetesSan Francisco, United StatesContact: Shylaja A Srinivasan, MDTaking people
About the trial
What the trial wants to find out
The purpose of this study to compare the typically prescribed dose of metformin (1000mg twice a day) with a higher dose of metformin (1350mg twice a day).
The 2 groups in the trial
- ExperimentalTreatment being tested
1350mg metformin twice per day
Treatment: Metformin
- Active ComparatorExisting treatment, for comparison
1000mg metformin twice per day
Treatment: Metformin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Pilot Study of Precision Dosing of Metformin in Youth With Type 2 Diabetes (PRECISE_T2D)
- Plain-language title
- Compares two metformin doses in young people with type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06120881, who can take part
- Record updated
- 23 December 2025